

Vandetanib ZETA

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



More serious and disabling adverse events observed



Other adjustments



Vandetanib ZETA

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Endocrine Tumours
 Therapeutic Indication: Treatment of aggressive and symptomatic MTC in patients with unresectable locally advanced or metastatic disease in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision
 Experimental Arm: Vandetanib
 Control Arm: Placebo



